Analyst consensus rating
Polaryx Therapeutics Analyst Rating: none
Direct answer
Polaryx Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.50.
Forecast evidence checked September 8, 2026.
Get free Polaryx Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.01
- Average price target
- $7.50
- High price target
- $10.00
- Low price target
- $6.00
- Low target gap
- +198.5%
- Target upside
- +273.1%
- High target gap
- +397.5%
- Target range width
- 199%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Polaryx Therapeutics?
Polaryx Therapeutics has a verified none consensus. The same dataset has an average price target of $7.50.
How far are Polaryx Therapeutics's low and high targets from the recorded price?
The low target implies +198.5%, while the high target implies +397.5%.
How many analysts are included in Polaryx Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Polaryx Therapeutics's target upside or downside calculated?
The average target of $7.50 is divided by the recorded price of $2.01, then one is subtracted to produce +273.1%. This does not guarantee a future return.
When was Polaryx Therapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.